Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
FGEN Stock Chart & Stats
$11.00
>-$0.01(-1.28%)
At close: 4:00 PM EST
$11.00
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$4.50 - $21.94
Previous CloseN/A
Volume937.77K
Average Volume (3M)30.76K
Market Cap
$44.48M
Enterprise Value$133.15M
Total Cash (Recent Filing)$23.37M
Total Debt (Recent Filing)$93.13M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Nov 10, 2025EPS Estimate
-4.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding4,043,899
10 Day Avg. Volume33,010
30 Day Avg. Volume30,760
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.99
Enterprise Value/Revenue-1.83
Enterprise Value/Gross Profit-2.30
Enterprise Value/Ebitda-1.03
Forecast
1Y Price Target
$43.00Price Target Upside290.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressFG-3246 is being investigated as a monotherapy in pre-chemotherapy mCRPC with a Phase II study initiated.
Regulatory AlignmentThe Type C meeting with the FDA clarified details for the upcoming Phase 3 study of roxadustat, which is expected to investigate its safety and efficacy in patients with anemia.
Strategic PartnershipThe sale of FibroGen China to AstraZeneca for approximately $220 million simplifies the company's balance sheet and extends its cash runway into 2028.
Bears Say
Clinical Trial RisksPotential risks include failed or inconclusive clinical trials, inability to secure adequate funding, and the occurrence of dilutive capital raises.
Competitive MarketThe mCRPC treatment landscape has become increasingly competitive, owing in large part to the commercial success of Pluvicto.
Financial PerformanceFibroGen reported 2Q25 financial results, posting EPS of ($1.88) compared to an estimate of $1.01 and consensus of $1.00.
FibroGen News
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $4.50 and its highest was $21.94 in the past 12 months.
What is FibroGen’s market cap?
FibroGen’s market cap is $44.48M.
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Nov 10, 2025 which is in 5 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on Aug 11, 2025. The company reported -$1.88 earnings per share for the quarter, beating the consensus estimate of -$2.303 by $0.423.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -4.01.
How many shares outstanding does FibroGen have?
FibroGen has 4,043,899 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of -$1.88 in its last earnings report, beating expectations of -$2.303. Following the earnings report the stock price went up 10.514%.
Which hedge fund is a major shareholder of FibroGen?
Currently, no hedge funds are holding shares in FGEN
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.00 (290.91% Upside)
$43.00 (290.91% Upside)
Hedge Fund Trend
Decreased
By 59.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.27%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with serious unmet medical needs. The company operates primarily in the areas of anemia, fibrotic diseases, and other related conditions. FibroGen's core products include Roxadustat, a drug designed to treat anemia associated with chronic kidney disease, which has received regulatory approvals in multiple markets.
FGEN Company Deck
FGEN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a predominantly positive outlook, driven by the increased financial consideration from the FibroGen China sale, which extends the company's cash runway significantly. The initiation of new clinical trials and positive regulatory feedback further support this sentiment. However, the limited revenue growth and ongoing net losses were noted as areas of concern.View all FGEN earnings summariesFGEN Stock 12 Month Forecast
Average Price Target
$43.00
▲(290.91% Upside)
Technical Analysis
Grace Therapeutics
―
Generation Bio
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―
Ownership Overview
14.61% Insiders
23.85% Mutual Funds
10.54% Other Institutional Investors
47.24% Public Companies and
Individual Investors